Skip to main content
. 2022 Jan 13;15:51–62. doi: 10.2147/CCID.S344445

Figure 3.

Figure 3

One month after Durvalumab was discontinued, the lesions resolved with post inflammatory hyperpigmentation on face (A), upper chest (B), back (C), and dorsum of both forearms (D).